Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 6, 2006, Pages 1299-1302

  Friedland, Gerald ^a,c,d   Khoo, Saye ^b   Jack, Christopher ^c   Lalloo, Umesh ^c  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Drug interactions; TB

Indexed keywords

DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ALCOHOLIC BEVERAGE; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONCENTRATION LOSS; DIRECTLY OBSERVED THERAPY; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LONGITUDINAL STUDY; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; NEGRO; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PSYCHOPATHY; SEX DIFFERENCE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; OXAZINES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; VIRAL LOAD;

EID: 33845361844     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl399     Document Type: Article

References (10)

1. World Health Organization. Interim Policy on Collaborative TB/HIV Activities. Geneva, Switzerland: WHO, 2004.
2. World Health Organization. Scaling up Antiretroviral Therapy in Resource Limited Settings. Guidelines for a Public Health Approach. Geneva, Switzerland: WHO, 2006.
3. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
4. Pozniak A, Miller R, Lipman M et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection. HIV Med 2005; 6: 62-83.
5. Jack C, Lalloo U, Abdool K et al. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36: 929-34.
6. Almond L, Hoggard P, Edirisinghe D et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-44.
7. Haas D, Ribaudo H, Kim R et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004; 8: 2391-400.
8. Almond L, Gibbons S, Davies G et al. A retrospective survey of the Liverpool TDM Service: Factors influencing efavirenz concentrations in patients taking rifampicin. Sixth International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, 2005. Abstract 19, p 15.
9. Brennan-Benson P, Lyus R, Harrison T et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: One size does not fit all. AIDS 2005; 19: 1541-6.
10. Manosuthi W, Sungkanuparph S, Thakkinstian A et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19: 1481-6.